Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00368550 · ClinicalTrials.gov registry record · Phase 4
Sertraline Pharmacotherapy for Alcoholism Subtypes
A Phase 4 study of Alcoholism, sponsored by UConn Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 134
- Enrollment target
- 1
- Study location
NCT00368550 is a Phase 4 study of Alcoholism that has completed, run by UConn Health. The registered enrollment target is 134 participants, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00368550, a Phase 4 study of Alcoholism, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 134 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether Sertraline, compared to placebo, is effective in the treatment of alcohol dependence as a function of the subtype of alcoholic patient being treated. This involved administering sertraline (to a maximum of 200 mg/day) or an inactive placebo for a 14-week treatment period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sertraline
Study Locations (1)
Connecticut
- University of Connecticut Health Center - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2004-02 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00368550
The ClinicalTrials.gov registry entry for NCT00368550 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (64% lower). The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00368550 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00368550 about?
NCT00368550 is a clinical study titled "Sertraline Pharmacotherapy for Alcoholism Subtypes". The purpose of this study is to determine whether Sertraline, compared to placebo, is effective in the treatment of alcohol dependence as a function of the subtype of alcoholic patient being treated. This involved administering sertraline (to a maximum of 200 mg/day) or an inactive placebo for a 14-...
What is the current status of trial NCT00368550?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 134 participants. The study started on 2004-02. Estimated completion is 2009-12.
What conditions does trial NCT00368550 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT00368550?
The interventions under investigation include: Placebo (DRUG), Sertraline (DRUG).
Who is sponsoring clinical trial NCT00368550?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00368550 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Naltrexone in AUD Reward Drinkers
RECRUITING · Phase 4
-
Naltrexone Treatment of Alcohol Abuse in Schizophrenia
COMPLETED · Phase 4
-
Naltrexone, Craving, and Drinking
COMPLETED · Phase 4
-
Naltrexone for Heavy Drinking in Young Adults
COMPLETED · Phase 4
-
Managing Alcoholism in People Who Do Not Respond to Naltrexone
COMPLETED · Phase 4
-
Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.